Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby
restoring normal tissue function,–. The interaction of menin with lysine methyltransferase 2A …

Menin inhibitors constitute a novel class of agents targeting the underlying biology of
nucleophosmin (NPM1) mutant and KMT2A (formerly known as MLL1) rearranged (KMT2Ar) …

The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the
cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic …

In parallel to the 5th edition of the World Health Organization Classification of
Haematolymphoid Tumours (WHO 2022), an alternative International Consensus …

PURPOSE Revumenib, an oral, small molecule inhibitor of the menin-lysine
methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase …

Balanced rearrangements involving the KMT2A gene (KMT2A r) are recurrent genetic
abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the …

Highlights•AML is a highly heterogeneous disease and warrants an individualized
approach.•The advent of effective low-intensity regimens has improved outcomes in older …

The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has
spurred the identification of therapeutic targets and the development of corresponding novel …

Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm characterized by
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …

Simple Summary The DEAD-box RNA helicase 41, DDX41, is one of the most frequently
identified mutations in myeloid neoplasms with germline predispositions, which represents …